About GEOVAX, INC.
GeoVax, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers. The company is advancing GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses, under an expedited regulatory pathway.
Development of vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancersAdvancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxvirusesClinical development of Gedeptin®, a novel oncolytic solid tumor gene-directed therapyConducting Phase 1/2 and planned Phase 2 clinical trials for Gedeptin® in combination with immune checkpoint inhibitorsResearch and development of preventive vaccines against hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg)
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to GEOVAX, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.